

STHLM3 - Prostate cancer diagnostic trial

Submission date 14/11/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/01/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/10/2022	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Prostate cancer is a leading cause of cancer death among men in the Western world. A PSA test looks for raised levels of PSA in the blood that may be a sign of prostate cancer in its early stages. Although PSA screening has been shown to prevent deaths, it can also lead to over-diagnosis (diagnosis of disease that would not have caused symptoms or death) and performing unnecessary biopsies (where a sample of the prostate is taken for diagnosis). The aim of this study is to assess whether a new biomarker test for prostate cancer can reduce how many men are referred to biopsy whilst still detecting high-risk prostate cancer. The study will also assess whether the new test decreases the number of low-risk prostate cancers diagnosed and improves the quality and effectiveness of prostate cancer diagnosis in routine health care in Stockholm.

Who can participate?

Men aged 50 to 69 living in Stockholm County Council or Region Gotland who have not previously been diagnosed with prostate cancer

What does the study involve?

Participants are randomly allocated to one of two groups. One group are referred to biopsy based on the PSA test result only. The other group are referred to biopsy based on their age, their genes, their family history and biomarkers.

What are the possible benefits and risks of participating?

There are no benefits for the participants other than a free prostate cancer test. There is a low risk of over-diagnosis of low-risk cancers.

Where is the study run from?

Karolinska Institutet (Sweden)

When is the study starting and how long is it expected to run for?

January 2013 to December 2014

Who is funding the study?

Stockholm County Council (Sweden)

Who is the main contact?
Prof. Henrik Grönberg

Contact information

Type(s)
Scientific

Contact name
Prof Henrik Grönberg

Contact details
Nobels väg 12
Stockholm
Sweden
17177

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
STHLM3 - Prostate cancer diagnostic randomized trial

Acronym
STHLM3

Study objectives
STHLM3 [STHLM relates to the city of Stockholm, Number 3 relates to that this is the third study within the same setting] is a randomized controlled trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for high risk prostate cancer.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Stockholm Ethical Review Board, 09/05/2012, ref: r DNR 2012/572-31/1

Study design
Two-armed randomized controlled trial

Primary study design
Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

The two study arms will be:

Control/PSA arm, where referral to biopsy will be based on Prostate-specific antigen (PSA) only with PSA ≥ 3 as the level of referral to prostate biopsy

Intervention/Best biomarker panel (BBP) arm, where referral to biopsy will be determined by a risk prediction model based on age, an array of single-nucleotide polymorphism (SNPs), family history and protein-based biomarkers.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

To increase the specificity of a combined prostate cancer test compared to the PSA test without decreasing the sensitivity of high risk of prostate cancers (defined as Gleason 7 or higher). The primary endpoint is number of prostate biopsies.

Key secondary outcome(s)

1. To decrease the number of low risk prostate cancers diagnosed
2. To increase the health related quality of life and knowledge of prostate cancer testing
3. To assess the health economic consequences of implementing prostate cancer screening
4. To improve the quality and effectiveness of prostate cancer diagnosis in the routine health care in Stockholm
5. To assess the overall long-term mortality of prostate cancer in the Stockholm/Gotland area over a 10-15 year period
6. To assess the combination of a blood based best biomarker panel and urine biomarkers in men with initial negative prostate biopsy (separate study protocol STHLM3-Rebiopsy) and
7. To facilitate inclusion in active surveillance protocol in men diagnosed with low risk prostate cancers

Completion date

31/12/2014

Eligibility

Key inclusion criteria

All men between 50 and 69 years of age who have a permanent postal address in Stockholm County Council or Region Gotland (N=260,000) will be asked whether they would like to take part in STHLM3.

Participant type(s)

All

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

Diagnosed with prostate cancer

Date of first enrolment

01/01/2013

Date of final enrolment

31/12/2014

Locations

Countries of recruitment

Sweden

Study participating centre

Nobels väg 12

Stockholm

Sweden

17177

Sponsor information

Organisation

Karolinska Institutet (Sweden)

ROR

<https://ror.org/056d84691>

Funder(s)

Funder type

Government

Funder Name

Stockholm County Council (Sweden)

Alternative Name(s)

Stockholm County Council

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Sweden

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2015		Yes	No
Results article		29/08/2022	04/10/2022	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes